• Successful and safe treatment of first patient with RC220 and RC220 in combination with doxorubicin
• Renewal of clinical team with new Chief Medical Officer and Vice President of Medical
• Continued disciplined capital management with $13.67m cash at quarter end

Race Oncology Limited (ASX: RAC) has released its Q4 FY2025 report, highlighting key milestones achieved in the June 2025 quarter. The company successfully treated the first patient with RC220 alone and in combination with doxorubicin in its Phase 1 clinical trial for advanced solid tumours, with no adverse events reported. This marks a significant progress in Race's RC220 cardioprotection + anticancer clinical program. Race also announced the appointments of Dr Jose Iglesias as Chief Medical Officer and Dr Simon Fisher as Vice President of Medical, strengthening its clinical leadership team. The company ended the quarter with $13.67 million in cash and cash equivalents, with over 83% of spending directed towards R&D and drug manufacturing activities. Race's prudent cash management places the company in an excellent position to fund all activities through CY2026. Other key events during the quarter include the activation of additional trial sites, the termination of a global license agreement, and the presentation of Race's work at industry conferences.

Race Oncology is focused on advancing its RC220 clinical program, with the goal of delivering cardioprotection and enhanced anticancer activity in solid tumours. The company is also exploring RC220 as a potential treatment for acute myeloid leukaemia. Race continues to explore partnerships, license agreements, or commercial merger and acquisition opportunities to accelerate access to bisantrene for cancer patients globally.